WIN will address the most critical question facing clinical cancer research: Why the improvement of survival still remains limited for most cancer patients? Save the date and register at: www.winsymposium.org
VILLEJUIF, France - Tuesday, December 15th 2015 [ME NewsWire]
(BUSINESS WIRE)-- WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to advancing personalized cancer medicine through global collaboration. This year WIN has chosen to address the critical question facing cancer research: How innovative use of targeted therapies can improve survival of greater numbers of cancer patients?
Under the chairmanship of Dr. Josep Tabernero, (Vall d’ Hebron, Spain), the WIN Symposium will present a unique opportunity by bringing together a forum of world-class experts from different backgrounds including patient advocacies, academic and private research institutes and industry to address contemporary challenges and controversies around the next innovative steps in cancer therapy that will significantly improve patients’ outcomes.
Themes that will be addressed:
Patients’ and advocacy perspectives
New tools for early diagnosis, selecting therapies and monitoring
Innovative clinical trials to substantially improve outcome
Relevant models and critical preclinical data before moving to the clinic
Translation of big data into clinical opportunities
“The annual symposium is the most visible part of the WIN Consortium’s activities, but perhaps the most exciting part of WIN is the engagement of all the different parties, from academic institutions to industry collaborators, and the unique opportunity this offers to truly collaborate in developing the next generation of clinical trials” John Mendelsohn, Chairman WIN Consortium, Director Khalifa Institute for Personalized Cancer Therapy, Past President, UT MDAnderson Cancer Center, USA.
WIN2016 Key dates
April 1, 2016
Early bird registration deadline
May 16, 2016
Abstract submission deadline
June 27-28, 2016
WIN 2016 Symposium
WIN 2016 will be happening around the UEFA European Football Championship (UEFA EURO 2016) in Paris. The delegates will have the opportunity to combine the best of science with this exceptional sports event. This will be a busy period, please book your travels in advance.
WIN2016 Venue Novotel Paris Centre Eiffel Tower, 61 quai de Grenelle, Paris, France
About WIN A worldwide network assembling all cancer stakeholders to develop cutting edge concepts and clinical trials that improve survival for cancer patients.
WIN members include organizations representing all stakeholders in precision cancer medicine: cancer centers in 17 countries across 4 continents, major technology and pharmaceutical companies and institutes, patient advocacies, and health payers.
For information about WIN Consortium, its mission, vision, members and activities, please visit: www.winconsortium.org
Contacts
Catherine Bresson, +33 1 45 59 58 43
Director of WIN Operational Team
Catherine.bresson@winconsortium.org
Permalink: http://www.me-newswire.net/news/16582/en
VILLEJUIF, France - Tuesday, December 15th 2015 [ME NewsWire]
(BUSINESS WIRE)-- WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to advancing personalized cancer medicine through global collaboration. This year WIN has chosen to address the critical question facing cancer research: How innovative use of targeted therapies can improve survival of greater numbers of cancer patients?
Under the chairmanship of Dr. Josep Tabernero, (Vall d’ Hebron, Spain), the WIN Symposium will present a unique opportunity by bringing together a forum of world-class experts from different backgrounds including patient advocacies, academic and private research institutes and industry to address contemporary challenges and controversies around the next innovative steps in cancer therapy that will significantly improve patients’ outcomes.
Themes that will be addressed:
Patients’ and advocacy perspectives
New tools for early diagnosis, selecting therapies and monitoring
Innovative clinical trials to substantially improve outcome
Relevant models and critical preclinical data before moving to the clinic
Translation of big data into clinical opportunities
“The annual symposium is the most visible part of the WIN Consortium’s activities, but perhaps the most exciting part of WIN is the engagement of all the different parties, from academic institutions to industry collaborators, and the unique opportunity this offers to truly collaborate in developing the next generation of clinical trials” John Mendelsohn, Chairman WIN Consortium, Director Khalifa Institute for Personalized Cancer Therapy, Past President, UT MDAnderson Cancer Center, USA.
WIN2016 Key dates
April 1, 2016
Early bird registration deadline
May 16, 2016
Abstract submission deadline
June 27-28, 2016
WIN 2016 Symposium
WIN 2016 will be happening around the UEFA European Football Championship (UEFA EURO 2016) in Paris. The delegates will have the opportunity to combine the best of science with this exceptional sports event. This will be a busy period, please book your travels in advance.
WIN2016 Venue Novotel Paris Centre Eiffel Tower, 61 quai de Grenelle, Paris, France
About WIN A worldwide network assembling all cancer stakeholders to develop cutting edge concepts and clinical trials that improve survival for cancer patients.
WIN members include organizations representing all stakeholders in precision cancer medicine: cancer centers in 17 countries across 4 continents, major technology and pharmaceutical companies and institutes, patient advocacies, and health payers.
For information about WIN Consortium, its mission, vision, members and activities, please visit: www.winconsortium.org
Contacts
Catherine Bresson, +33 1 45 59 58 43
Director of WIN Operational Team
Catherine.bresson@winconsortium.org
Permalink: http://www.me-newswire.net/news/16582/en
No comments:
Post a Comment